In fact, we found that treatment with the TORC1/2 inhibitor MLN0128 led to downregulation of p-4E-BP1 and MCL-1 in MYCN-amplified neuroblastomas (Figure S5A), which demonstrated that MCL-1 in these cancers is downregulated following inhibition of p4E-BP1. Here, MYCN is linked to cancer.